WithdrawnPhase 1NCT05176691
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
Studying B-cell chronic lymphocytic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hutchmed
- Principal Investigator
- Vijay Jayaprakash, MBBS, PHD, M.D., PhDHutchison Medipharma Limited
- Intervention
- HMPL-760(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2022
Study locations (30)
- Innovative Clinical Research, Anaheim, California, United States
- Emory University Hospital, Atlanta, Georgia, United States
- Tulane Cancer Center, New Orleans, Louisiana, United States
- Johns Hopkins Clinical Research Center, Baltimore, Maryland, United States
- AMR Kansas City, Formerly Center for Pharmaceutical Research, an AMR company, Kansas City, Missouri, United States
- Center For Advanced Medicine, St Louis, Missouri, United States
- Summit Medical Group, Florham Park, New Jersey, United States
- New York University Langone Med Center. Lab, New York, New York, United States
- Clinical Research Alliance, Westbury, New York, United States
- Renovatio Clinical, El Paso, Texas, United States
- Oncology Consultants, P.A., Houston, Texas, United States
- Renovatio Clinical, The Woodlands, Texas, United States
- Royal Adelaide Hospital, Adelaide, South Australia, Australia
- Centre Antoine Lacassagne, Nice, Alpes Maritimes, France
- Hôpital Saint-Antoine, Paris, Paris, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05176691 on ClinicalTrials.govOther trials for B-cell chronic lymphocytic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07194980Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaFred Hutchinson Cancer Center
- RECRUITINGEARLY PHASE1NCT07428707Immune Profiling of CLL/SLL Treated With First-Line PirtobrutinibNational Heart, Lung, and Blood Institute (NHLBI)
- RECRUITINGPHASE4NCT07218341A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaEli Lilly and Company
- RECRUITINGPHASE1NCT06859008Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaCity of Hope Medical Center
- RECRUITINGPHASE2NCT07271667A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesCuris, Inc.
- RECRUITINGPHASE2NCT07014917Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLLZulfa Omer
- RECRUITINGPHASE2NCT06958705Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor MonotherapyThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGPHASE1, PHASE2NCT07052695Mosunetuzumab for CLL MRD ClearanceInhye Ahn